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Abstract
Background and Objectives Edoxaban is an oral, once-
daily direct factor Xa inhibitor. To support the possibility
that patients may choose to switch treatment from another
nonvitamin K antagonist oral anticoagulant to edoxaban,
this clinical study was conducted to evaluate the pharma-
cokinetic and pharmacodynamic effects of edoxaban after
switching from rivaroxaban or dabigatran etexilate to
edoxaban.
Methods In this open-label, three-period, crossover study,
healthy subjects received 3 days of edoxaban 60 mg daily,
rivaroxaban 20 mg daily, or dabigatran etexilate 150 mg
twice daily, followed by edoxaban 60 mg on day 4.
Results Day 4 edoxaban pharmacokinetic parameters
were similar for all treatments. The peak effect of edoxa-
ban on prothrombin time (PT) after 4 days of edoxaban
only was 21.8 ± 2.46 s; after switching from rivaroxaban
to edoxaban, peak effect on PT was similar at
21.8 ± 2.88 s. After switching from dabigatran etexilate to
edoxaban, least squares mean activated partial thrombo-
plastin time (aPTT) at 2 h after administration was 47.6 vs
35.0 s for edoxaban alone. The treatment difference was
12.8 s (95 % confidence interval 10.5–15.1; p\ 0.0001).
Post hoc analysis revealed that predose aPTT was elevated
on day 3 of dabigatran etexilate administration, and on day
4, indicating a carryover effect from dabigatran. All
treatments were well tolerated and there were no safety
concerns upon switching, with no increased risk of
bleeding.
Conclusions The study results suggest that switching to
edoxaban from either rivaroxaban or dabigatran etexilate at
the time of the next dose is well tolerated and maintains
coagulation status.
Key Points
Switching from rivaroxaban or dabigatran etexilate
to edoxaban at the next scheduled dosing time
produces a similar effect on anticoagulant
biomarkers as continuing on these drugs.
In most instances, subjects switching to edoxaban
from rivaroxaban or dabigatran etexilate can initiate
therapy at the next scheduled dosing time.
1 Introduction
Edoxaban, a nonvitamin K antagonist oral anticoagulant
(NOAC), is an oral, once-daily, direct, specific, and
reversible inhibitor of activated clotting factor X (FXa) [1,
2]. Edoxaban 60 mg once daily has been approved in the
US for the prevention of stroke and systemic embolic
events in patients with nonvalvular atrial fibrillation, and
for the treatment of venous thromboembolism (VTE) [2].
Other approved NOACs include the FXa inhibitors
rivaroxaban [3] and apixaban [4], and the direct thrombin
inhibitor dabigatran etexilate [5]. Compared with vitamin
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K antagonists such as warfarin, NOACs provide simple
dosing and freedom from frequent coagulation monitoring,
along with broader therapeutic windows.
Edoxaban is rapidly absorbed, reaching peak plasma
concentration and peak antithrombotic effect within 1–2 h
[6], with an oral bioavailability of approximately 62 % [7]
and a terminal elimination half-life of 10–14 h [8, 9]. The
time course profiles of biomarkers indicative of anticoag-
ulant activity closely parallel edoxaban’s plasma concen-
tration–time course profile. These include anti-factor Xa
(anti-FXa), prothrombin time (PT), activated partial
thromboplastin time (aPTT), and thrombin generation
parameters.
To support the possibility that patients may switch
treatment from another NOAC to edoxaban, this clinical
study was conducted in healthy subjects to evaluate the
pharmacokinetic and pharmacodynamic effects of edoxa-
ban after switching from steady-state rivaroxaban or
dabigatran etexilate to edoxaban. The principal pharma-
codynamic measures were PT and aPTT, which are con-
sidered most sensitive for rivaroxaban and dabigatran,
respectively, as indicated in their product labels [3, 5]. For
completeness, other biomarkers (including anti-FXa and
thrombin generation parameters) were also assessed.
2 Methods
2.1 Study Design
This was an open-label, randomized, three-period, cross-
over study at a single center in the US. The study was
conducted in compliance with the Declaration of Helsinki
and in accordance with Good Clinical Practice guidelines
and the International Conference on Harmonisation. All
study procedures were approved by the IntegReview
Institutional Review Board (Austin, TX, USA), and
informed consent was obtained from all individual partic-
ipants included in the study.
The three treatments were: (1) edoxaban 60 mg
(Savaysa; Daiichi Sankyo, Inc.) once daily for 4 days;
(2) rivaroxaban 20 mg (Xarelto; Janssen Ortho, LLC)
once daily for 3 days and (3) dabigatran etexilate 150 mg
(Pradaxa; Boehringer Ingelheim) twice daily for 3 days,
with treatments 2 and 3 followed by a single oral dose of
edoxaban 60 mg on day 4. Meal times and contents were
standardized during treatment periods. On days of blood
sampling for pharmacokinetics, edoxaban was adminis-
tered in the morning with 240 mL of water, following an
overnight fast of at least 10 h. Rivaroxaban was admin-
istered with breakfast, while dabigatran etexilate and
edoxaban were administered under fasting conditions on
days 1–3. On day 4 of all treatments, subjects continued
to fast for an additional 4 h after edoxaban administration,
with water allowed ad libitum except for 1 h before and
after dosing. All treatments were administered in the
morning. Each treatment period lasted 5 days, with a
washout period of 7 days between treatment periods
(Fig. 1).
Blood samples for the quantification of edoxaban
plasma concentrations and for pharmacodynamic and bio-
marker assessments were collected on day 1 of treatment 1
and on day 4 for all treatments at 0 (predose), 0.5, 1, 1.5, 2,
3, 4, 6, 10, 14, and 24 h postdose. Additional serial blood
samples were collected on day 3 of treatment 2, and were
collected at 0 (predose), 1, 2, 3, 4, 6, 12, and 24 h postdose,
and at 0 (predose), 1, 2, 4, 6, and 24 h postdose for the
determination of the pharmacokinetics and pharmacody-
namics of rivaroxaban. Similarly, additional serial blood
samples were collected on day 3 of treatment 3 for the
characterization of the pharmacokinetics of dabigatran at 0
(predose), 1, 1.5, 2, 3, 4, and 12 h postdose, and at 0
(predose), 1, 2, 4, and 12 h postdose for characterization of
pharmacodynamics assessments.
Fig. 1 Study design. Treatment 1: edoxaban 60 mg once daily for
4 days; treatment 2: rivaroxaban 20 mg once daily for 3 days
followed by a single oral dose of edoxaban 60 mg on day 4;
treatment 3: dabigatran etexilate 150 mg twice daily for 3 days
followed by a single oral dose of edoxaban 60 mg on day 4
128 D. A. Parasrampuria et al.
2.2 Study Population
Subjects were healthy men and women, 18–45 years of
age, with a body mass index (BMI) of 18–30 kg/m2.
Subjects had normal coagulation values for PT/interna-
tional normalized ratio (INR) and aPTT. Exclusion criteria
included a history of major bleeding, major trauma, or
major surgical procedure of any type within 6 months of
the first dose of study medication; a history of minor
bleeding within 3 months before the first dose of study
medication; a history of peptic ulcer, gastrointestinal
bleeding, or bleeding from hemorrhoids; a family history
(suspected or documented) of coagulopathy; use of anti-
coagulants, coagulants, or antiplatelet therapy within
30 days before the first dose of study medication; use of
any drugs or substances known to be strong inhibitors or
strong inducers of cytochrome P450 (CYP) 3A4/5 enzymes
or p-glycoprotein within 28 days before the first dose of
study medication; and use of fish oil, acetylsalicylic acid,
any over-the-counter medication containing acetylsalicylic
acid, nonsteroidal anti-inflammatory drugs, or other sup-
plements (e.g. ginkgo biloba) that could prolong bleeding
within 14 days before the first dose of study medication.
The use of any of the above mentioned agents during the
study was also prohibited. Subjects agreed to abstain from
alcohol and specified caffeinated food and drink from
2 days prior to dosing through day 5 of each treatment
period, and from food and beverages containing grapefuit
or Seville oranges from 10 days before first dosing through
the end of the study.
2.3 Bioanalytical Analysis
Human plasma samples were analyzed for edoxaban using
a liquid chromatographic method with tandem mass spec-
trometric detection, developed and validated at Advion
BioServices (Ithaca, NY, USA). The assay was linear over
the range of 0.764–382 ng/mL for edoxaban. The intra-
and interassay precision for quality control samples pre-
pared at 0.764, 2.29, 153, and 306 ng/mL were B11.0 and
B8.8 %, respectively. The intra- and interassay accuracy of
these quality control samples were -6.9 to 5.8 % for
edoxaban.
Human plasma samples were analyzed by Worldwide
Clinical Trials (San Antonio, TX, USA) for free (uncon-
jugated) dabigatran and for rivaroxaban. Quantitations
were performed using weighted 1/x2 linear least squares
(LS) regression analyses generated from calibration stan-
dards. For rivaroxaban, the method was validated for a
range of 0.500–500 ng/mL, based on the analysis of
0.100 mL of plasma. The quality control intraday precision
and accuracy ranges were 0.7–4.2 and -3.2 to 6.7 %,
respectively. The quality control interday precision and
accuracy ranges were 1.0–3.1 and -1.6 to 5.3 %, respec-
tively. For dabigatran, the method was validated for a range
of 0.500–300 ng/mL, based on the analysis of 0.200 mL of
plasma. The quality control intraday precision and accu-
racy ranges were 1.1–5.8 and -12.0 to -3.0 %, respec-
tively. The interday precision and accuracy ranges were
2.7–6.1 and -7.3 to -5.0 %, respectively.
2.4 Pharmacokinetic Analyses
Data from all dosed subjects were analyzed. Plasma con-
centration–time data for edoxaban were analyzed by non-
compartmental methods using PhoenixTM WinNonlin
version 6.1 (Pharsight Corporation, St. Louis, MO, USA).
The following parameters were assessed: maximum plasma
concentration (Cmax), time to Cmax (Tmax), area under the
plasma concentration–time curve during the dosing interval
calculated using the linear trapezoidal rule (AUCs), and the
day 4 to day 1 accumulation ratio for AUCs. Additionally,
trough concentrations (Ctrough) were reported for each
treatment.
2.5 Biomarker Analysis
Biomarkers were measured using validated methods at
Medpace Reference Laboratories (Cincinnati, OH, USA).
PT was measured on the Stago PT platform (Parsippany,
NJ, USA), using Neoplastin C1? as the thromboplastin to
measure plasma clotting time. The intraday and interday
precision ranges were 0.5–1.8 and 1.8–2.2 %, respectively,
and bias ranged from -4.0 to 6.4 %.
aPTT was measured in duplicate on the Siemens (Er-
langen, Germany) BCS hemostasis analyzer. Calcium was
added to trigger the coagulation process and clotting time
was measured. The intraday and interday precision ranges
were 0.9–1.0 and 2.4–7.9 %, respectively, and bias ranged
from -15.6 to -8.5 %.
Anti-FXa was measured using the Biophen heparin 6
assay (Aniara, West Chester, OH, USA). The intraday and
interday precision ranges were 3.1–4.9 and 4.8–10.0 %,
respectively, and bias reported in two tables within the
analytical report ranged from -7.7 to 3.9 and -16.7 to
-4.3 %.
The Technothrombin thrombin generation assay
(TGA) (Technoclone, Vienna, Austria) measured fluores-
cence generated by cleavage of a specific thrombin sub-
strate. The interday precision ranged from 10.4 to 27.1 %,
while the intraday precision ranges were 7.9–8.3 % for lag
time, 3.0–6.0 % for time to peak, 5.2–9.5 % for peak,
14.5–20.2 % for velocity, and 2.5–6.0 % for endogenous
thrombin potential (ETP). The bias ranged from -3.8 to
30.9 %.
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2.6 Pharmacodynamic Assessments
Data from all dosed subjects were analyzed. Biomarker
time course profile data were analyzed by noncompart-
mental methods using PhoenixTM WinNonlin version 6.1
(Pharsight Corporation, St. Louis, MO, USA). The fol-
lowing parameters were assessed: minimum observed
activity level (Amin), maximum observed activity level
(Amax), time to maximum observed activity value (Tmax),
area under the effect–time curve during dosing interval
calculated using the linear trapezoidal rule (AUEs), change
from maximum activity relative to baseline (DAmax), and
percent change in maximum activity relative to baseline
(%DAmax). The primary endpoint was the 2-h assessment of
PT on day 4 when comparing edoxaban with rivaroxaban,
and of aPTT on day 4 when comparing edoxaban with
dabigatran etexilate. This 2-h timepoint was chosen as it is
close to peak effect.
2.7 Safety Assessment
Safety assessments included monitoring of incidence and
severity of adverse events (AEs); physical examination
findings; vital signs; 12-lead electrocardiograms; standard
hematology, clinical chemistry, coagulation (PT/INR and
aPTT) and urinalysis laboratory tests; and fecal occult
blood tests.
2.8 Statistical Analysis
The pharmacokinetic and pharmacodynamic parameters
were summarized using descriptive statistics for all dosed
subjects using SAS version 9.2. Statistical comparison
between treatments was performed on day 4 data for the
most sensitive biomarker of interest for the anticoagulant
that was administered prior to switching to edoxaban. The
reference was edoxaban administered alone for a similar
duration. The primary endpoint selected for this statistical
comparison was the 2-h assessment, as it was close to peak
effect. For switching from rivaroxaban, PT measurement at
2 h was used; while for switching from dabigatran etexi-
late, aPTT measurement at 2 h was used. Although the 2-h
time point was chosen for primary statistical analyses and
sample size, the overall assessment of the effects of treat-
ment switch was made based on the totality of the data and
clinical interpretation of the results. Treatment differences
were evaluated using an analysis of covariance
(ANCOVA) model, fitting the absolute PT or aPTT values
as the response variable with baseline (predose on day 1 of
treatment 1) PT or aPTT as the covariate and with factors
for treatment, treatment sequence, and period fitted as fixed
effects. Subject nested within treatment sequence was
included as a random effect term. If the 95 % CI for the
treatment difference (treatment 2 vs 1) in PT was within the
interval (-1.5, 1.5), then the PT values were considered
equivalent between the two treatments. If the 95 % CI for
the treatment difference (treatment 3 vs 1) in aPTT was
within the interval (-6.5, 6.5), then the aPTT values were
considered equivalent between the two treatments.
2.9 Sample Size Considerations
Based on previous trials of edoxaban, a total of 18 healthy
subjects was expected to provide 90 % power for the test of
equivalence for PT, with an equivalence margin of 1.5,
a = 0.05, if the difference in means was 0.2 with standard
deviation (SD) = 1.2; and to provide 90 % power for the
test of equivalence for aPTT, with an equivalence margin
of 6.5, a = 0.05, if the difference in means was 2 with
SD = 4.2. Therefore, a total of 24 subjects were planned
for study enrollment, with no replacement of dropouts.
3 Results
3.1 Subjects
Twenty-four subjects were randomized to one of six
treatment sequences in this three-treatment crossover
study. Two subjects did not complete all three treatments.
Subjects had a mean age of 31 years, and the majority of
subjects were White (58 %) and male (58 %), with an
average body weight of 74.1 ± 12.4 kg and a BMI of
26.1 ± 2.7 kg/m2 (Table 1).
Table 1 Subject demographics
Variable N = 24
Age (years; mean ± SD) 30.8 ± 8.1





American Indian/Alaskan native 4 (16.7)
Black or African American 5 (20.8)




Height (cm; mean ± SD) 168.1 ± 8.9
Weight (kg; mean ± SD) 74.1 ± 12.4
BMI (kg/m2; mean ± SD) 26.1 ± 2.7
BMI body mass index, SD standard deviation
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3.2 Pharmacokinetics
When administered once daily, the mean edoxaban plasma
concentration–time profile after a single dose on day 1 was
similar to that on day 4 (Fig. 2), with minimal accumula-
tion upon multiple dosing. Edoxaban Ctrough were similar
on days 4 (15.4 ± 6.19 ng/mL) and 5 (15.5 ± 3.98 ng/
mL), indicating that steady state was achieved by day 4 of
once-daily edoxaban administration. Pharmacokinetic
parameters were similar following single- and multiple-
dose administration of edoxaban (Table 2) due to the
minimal accumulation.
Upon switching from rivaroxaban to edoxaban, or from
dabigatran etexilate to edoxaban, the concentration–time
profile of edoxaban was similar to edoxaban when
administered alone. Pharmacokinetic parameters were also
similar following treatment with edoxaban alone or upon
switching from rivaroxaban or dabigatran etexilate to
edoxaban (Table 2). The most relevant comparison for
pharmacokinetics after switching is day 1 administration of
edoxaban in treatment 1. As can be seen from the results,
the single-dose pharmacokinetic parameters of edoxaban
administered alone and after switching were similar.
The mean pharmacokinetic parameters Cmax and
AUCs ± SD on day 3 for rivaroxaban were
408 ± 97.8 ng/mL and 3050 ± 556 ngh/mL, and
140 ± 42.3 ng/mL and 921 ± 265 ngh/mL for dabiga-
tran, respectively. These were comparable to published
values and demonstrate adequate exposure to these drugs in
this study [10, 11].
3.3 Pharmacodynamics
3.3.1 Treatment Over 4 Days with Edoxaban Alone
The time course profiles of PT (Fig. 3a), aPTT (Fig. 4a),
and anti-FXa (Fig. 5) paralleled the concentration–time
profile of edoxaban, with a rapid increase to peak effect
within 1–2 h, followed by a return to baseline by 24 h.
Repeat dosing did not cause additive anticoagulatory
effects, as assessed by these biomarkers. Of note, there was
a linear relationship between PT, aPTT, anti-FXa, and
plasma edoxaban concentration (data not shown). Further,
thrombin generation parameters were similar upon single
and repeat dosing (Table 3). These data indicate that
maximum anticoagulatory effects are observed with the
first dose of edoxaban, and that the anticoagulatory effects
are consistent upon multiple dosing.
3.3.2 Switching to Edoxaban After 3 Days of Once-Daily
Rivaroxaban Dosing
Upon switching from rivaroxaban to edoxaban, the time
course profile of PT was similar to that observed with
edoxaban administered alone (Fig. 3b). The peak effect of
edoxaban on PT was similar for both treatments:
21.8 ± 2.88 s on day 4 of treatment 2 after switching from
Fig. 2 Mean edoxaban plasma concentration for 24 h after dosing
on day 1 or 4 after treatment 1 (edoxaban alone). Error bars represent
the standard deviation
Table 2 Pharmacokinetic parameters of edoxaban administered alone or following a switch from rivaroxaban or dabigatran
Treatment Edoxaban
Day 1 (treatment
1) (n = 23)
Edoxaban
Day 4 (treatment
1) (n = 23)
Edoxaban after switching
from rivaroxaban
Day 4 (treatment 2)
(n = 24)
Edoxaban after switching from
dabigatran etexilate
Day 4 (treatment 3) (n = 23)
Cmax (ng/mL) 309 ± 97.2 303 ± 87.7 288 ± 113 280 ± 124
Tmax (h) 1.00 (1.00, 2.00) 1.50 (0.50, 4.00) 1.00 (0.50, 2.00) 1.00 (0.50, 3.00)
AUCs (ngh/mL) 1780 ± 319 1990 ± 403 1740 ± 353 1680 ± 475
Ctrough (ng/mL) 14.0 ± 5.44 15.5 ± 3.98 13.4 ± 5.00 12.8 ± 4.13
Accumulation ratio [AUCs (day
4)/AUCs (day 1)]
– 1.14 ± 0.25 – –
Data are expressed as arithmetic mean ± standard deviation, except for Tmax, which is expressed as median (minimum, maximum)
AUCs area under the concentration–time curve during the 24 h dosing interval, Cmax maximum plasma concentration, Ctrough trough concen-
tration, Tmax time to reach maximum plasma concentration
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rivaroxaban, and 21.8 ± 2.46 s on day 4 of treatment 1,
edoxaban alone (Table 3). Other day 4 pharmacodynamic
parameters were also similar between the two treatment
regimens (Table 3).
LSmean PT at 2 h after dosing (a time point close to Tmax)
was 20.8 s for the regimen of edoxaban after switching from
rivaroxaban, and 20.6 s for edoxaban alone. The treatment
difference was 0.25 s (95 % confidence interval [CI] -1.23
to 1.73; p = 0.734). Assessments of aPTT (Table 3), anti-
FXa (Table 3), and TGA parameters (Table 4) were also
similar between the two treatment regimens.
3.3.3 Switching to Edoxaban After 3 Days of Twice-Daily
Dabigatran Etexilate Dosing
Mean changes in clotting time after treatment with edox-
aban on day 4, as measured by aPTT, were higher after
switching from dabigatran etexilate than after treatment
with edoxaban alone (Fig. 4b). For treatment regimens of
Fig. 3 Mean plasma prothrombin time: a day 1 or 4 after treatment 1
(edoxaban alone); b day 4 after treatment 1 (edoxaban alone) or
treatment 2 (edoxaban after switching from rivaroxaban). Error bars
represent the standard deviation
Fig. 4 Mean plasma activated partial thromboplastin time: a day 1
or 4 after treatment 1 (edoxaban alone); b day 4 after treatment 1
(edoxaban alone) or treatment 3 (edoxaban after switching from
dabigatran etexilate); c for treatment 3, day 3 treatment with
dabigatran etexilate or day 4 treatment with edoxaban after switching
from dabigatran etexilate. Error bars represent the standard deviation
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edoxaban after switching from dabigatran etexilate and
edoxaban alone, respectively, on day 4, mean Amax val-
ues ± SD were 50.8 ± 8.92 and 35.9 ± 3.15 s; median
Tmax values (min, max) were 1.00 (0.50, 3.00) and 1.50
(0.50, 4.00) (Table 3).
LS mean aPTT at 2 h after dosing was 47.6 s after
switching from dabigatran etexilate to edoxaban versus
35.0 s for edoxaban alone. The treatment difference was
12.8 s (95 % CI 10.5–15.1; p\ 0.0001). Due to this
observation, a post hoc analysis was conducted to assess if
this difference was due to lingering effects of dabigatran
etexilate twice-daily treatment rather than an edoxaban
effect. As shown in Fig. 4b, c (the post hoc comparison for
this treatment regimen between day 3 with dabigatran
etexilate and day 4 after switching to edoxaban), predose
aPTT was elevated on both days 3 and 4, indicating that
this was indeed a dabigatran effect (Fig. 4c).
Increased anticoagulation in subjects who switched to
edoxaban after treatment with dabigatran etexilate com-
pared with those treated with edoxaban alone was also
suggested by three of the TGA parameters. Edoxaban
treatment on day 4 after switching from dabigatran etexi-
late compared with continual edoxaban treatment resulted
in ETP Amax values of 3338 ± 575 mNmin and
3644 ± 434 mNmin, lag time Amax values of 55.3 ± 16.2
and 37.8 ± 7.09 min, and time-to-peak Amax values of
74.0 ± 12.4 and 58.5 ± 12.2 min, respectively (Table 4).
However, other thrombin generation parameters such as
velocity and peak thrombin were similar between the two
regimens (Table 3), as were elevations in PT (Table 3) and
anti-FXa (Table 3).
Fig. 5 Mean plasma anti-FXa on day 1 or 4 after treatment 1
(edoxaban alone). Error bars represent the standard deviation
Table 3 Pharmacodynamic parameters on day 4
Parameter Edoxaban alone (treatment
1) (n = 23)
Edoxaban after switching from
rivaroxaban (treatment 2) (n = 24)
Edoxaban after switching from
dabigatran etexilate (treatment 3) (n = 23)
Prothrombin time
Amax (s) 21.8 ± 2.46 21.8 ± 2.88 24.6 ± 4.25
Tmax (h) 1.50 (0.50, 4.00) 1.04 (0.50, 2.00) 1.00 (0.50, 3.00)
AUEs (sh) 382 ± 16.2 383 ± 14.7 398 ± 21.5
Amin (s) 13.7 ± 0.46 13.9 ± 0.61 14.1 ± 0.65
DAmax (s) 8.58 ± 2.39 8.72 ± 2.95 11.7 ± 4.15
Activated partial thromboplastin time
Amax (s) 35.9 ± 3.15 36.5 ± 3.94 50.8 ± 8.92
Tmax (h) 1.50 (0.50, 4.00) 1.00 (0.50, 4.00) 1.00 (0.50, 3.00)
AUEs (sh) 725 ± 48.8 738 ± 58.6 863 ± 87.3
Amin (s) 27.7 ± 1.70 28.4 ± 2.13 30.0 ± 2.20
DAmax (s) 9.18 ± 2.11 9.73 ± 3.54 24.3 ± 8.35
Anti-FXa
Amax (IU/mL) 3.14 ± 0.944 3.23 ± 1.10 2.83 ± 1.27
Tmax (h) 1.50 (0.50, 4.00) 1.50 (0.50, 2.00) 1.00 (0.50, 3.00)
AUEs (IU/mLh) 20.7 ± 4.36 21.9 ± 5.26 17.3 ± 5.31
Amin (IU/mL) 0.12 ± 0.03 0.17 ± 0.09 0.100 ± 0.000
DAmax (IU/mL) 3.04 ± 0.945 3.15 ± 1.12 2.81 ± 1.24
Data are expressed as arithmetic mean ± standard deviation, except for Tmax, which is expressed as median (minimum, maximum)
DAmax change in maximum activity relative to baseline, Amax maximum observed activity, Amin minimum observed activity, AUEs area under the
concentration–time curve during the 24 h dosing interval, Tmax time to reach maximim observed activity
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3.4 Safety
Edoxaban, dabigatran etexilate, and rivaroxaban were
well tolerated in healthy adult subjects. No subjects
withdrew from the study due to treatment-emergent AEs
(TEAEs). One subject had mildly elevated creatine kinase
levels at a period 2 check-in that were not considered by
the investigator to be related to the study drug. The
subject was not dosed in period 2; however, the subject
was allowed to return for period 3 dosing. The most
common (C2 subjects during any treatment) TEAEs were
dizziness (one subject in treatment 2, four subjects in
treatment 3), constipation (two subjects in treatment 1,
two subjects in treatment 2), diarrhea (one subject in
treatment 1, two subjects in treatment 3), vessel puncture
site hemorrhage (two subjects in treatment 3), and nausea
(one subject in treatment 3, two subjects in treatment 3).
Similar proportions of subjects across treatments experi-
enced TEAEs during the study, and all TEAEs were mild
or moderate in intensity.
4 Discussion
This is the first study to address the effects of switching
from other NOACs to edoxaban. Studying pharmacokinetic
parameters of edoxaban and pharmacodynamic measures
of coagulation after switching from another NOAC can
provide clinical guidance for physicians and their patients
who may choose to switch from another NOAC to edox-
aban. In this study of healthy subjects, steady-state condi-
tions were achieved by 4 days of once-daily edoxaban
treatment. We compared 4 days of continual treatment with
edoxaban with the immediate effects of switching to
edoxaban from previous treatment with rivaroxaban or
dabigatran etexilate on day 4. Edoxaban was well tolerated
when administered alone or upon switching from dabiga-
tran etexilate or rivaroxaban.
Switching from rivaroxaban to edoxaban on day 4 did
not lead to any relevant differences in edoxaban pharma-
cokinetics or pharmacodynamics compared with 4 days of
continual edoxaban treatment. All edoxaban pharmacoki-
Table 4 Thrombin generation parameters
Parameter Edoxaban alone
Day 1 (treatment 1)
(n = 23)
Edoxaban alone
Day 4 (treatment 1)
(n = 23)
Edoxaban after switching from
rivaroxaban
Day 4 (treatment 2) (n = 24)
Edoxaban after switching from
dabigatran etexilate
Day 4 (treatment 3) (n = 23)
Endogenous thrombin potential
Amin (nMmin) 1520 ± 754 1474 ± 755 1506 ± 798 1239 ± 828
Amax (nMmin) 3635 ± 432 3644 ± 434 3680 ± 462 3338 ± 575
DAmax (%) 5.54 ± 5.99 6.21 ± 11.3 7.49 ± 14.0 -3.80 ± 11.4
Lag time
Amin (min) 15.8 ± 2.25 16.9 ± 2.41 15.8 ± 3.54 20.5 ± 3.60
Amax (min) 38.3 ± 8.59 37.8 ± 7.09 39.9 ± 9.96 55.3 ± 16.2
DAmax (%) 130 ± 46.3 129 ± 52.6 139 ± 63.0 238 ± 100
Time to peak
Amin (min) 22.2 ± 4.13 23.7 ± 4.29 22.0 ± 5.15 27.5 ± 7.94
Amax (min) 58.6 ± 12.6 58.5 ± 12.2 59.4 ± 14.6 74.0 ± 12.4
DAmax (%) 152 ± 50.7 154 ± 63.9 155 ± 72.0 225 ± 71.8
Velocity
Amin (nM/min) 2.62 ± 1.92 2.40 ± 1.89 3.04 ± 2.88 2.13 ± 1.35
Amax (nM/min) 61.4 ± 31.3 58.4 ± 31.9 67.4 ± 46.6 46.5 ± 25.7
DAmax (%) 30.7 ± 52.2 68.4 ± 179 78.1 ± 173 8.84 ± 70.9
Peak thrombin
Amin (nM) 45.7 ± 25.5 43.4 ± 25.1 49.2 ± 31.9 48.9 ± 25.2
Amax (nM) 323 ± 98.1 315 ± 90.6 324 ± 123 302 ± 77.0
DAmax (%) 12.4 ± 21.4 18.7 ± 56.2 18.2 ± 58.2 9.28 ± 39.4
Data are expressed as arithmetic mean ± standard deviation
%DAmax percent change in maximum activity relative to baseline, Amax maximum observed activity value, Amin minimum observed activity value
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netic parameters examined on day 4, immediately after
switching treatment, were unchanged compared with
steady state. The pharmacodynamic marker PT, affected by
rivaroxaban in a dose-dependent manner and considered to
be sensitive to rivaroxaban [12], also did not differ after
switching compared with continual edoxaban treatment
(p = 0.734). Of note, a sensitive thromboplastin was
employed for the measurement of PT to ensure adequate
sensitivity to pick up any differences. The 95 % CI around
the difference in LS means (-1.23, 1.73) was slightly
outside the predetermined criteria for establishing equiva-
lence (-1.5, 1.5). However, the LS means were compara-
ble (20.8 s after the switch vs. 20.6 s for edoxaban alone).
The wider-than-expected range of the 95 % CI is likely due
to the small sample size and the relatively unexpected high
variability of the raw data. Secondary measures of anti-
coagulation also showed close similarity between treatment
with edoxaban after switching from rivaroxaban compared
with treatment with edoxaban alone. In total, the results
suggest that switching from rivaroxaban to edoxaban will
maintain patients’ anticoagulated status.
Switching from dabigatran etexilate to edoxaban on day
4 also did not lead to any relevant differences in edoxaban
pharmacokinetics compared with 4 days of treatment with
edoxaban alone. A residual effect of dabigatran was
observed on the pharmacodynamic marker aPTT, selected
for its sensitivity to dabigatran. aPTT was significantly
higher after the switch from dabigatran etexilate compared
with treatment with edoxaban alone, and the 95 % CI of
the treatment difference was outside the range of equiva-
lence. In addition, predose aPTT values were higher on
both days 3 and 4 of treatment 3 (edoxaban on day 4
preceded by 3 days of dabigatran etexilate) compared with
predose aPTT in those treated with edoxaban alone. This
finding is consistent with the reported pharmacology of
dabigatran. The aPTT assay is not suitable for precise
quantification of anticoagulant effect, and aPTT is less
sensitive to edoxaban than to dabigatran, therefore the
additive effect of the two anticoagulants cannot be quan-
tified. A carryover anticoagulation effect of dabigatran is
supported by changes in the TGA parameters, ETP, lag
time, and time to peak. However, not all coagulation
markers supported the residual effect of dabigatran. The
implication of the residual effect on safety is unknown.
Overall assessment of the ability to switch from rivaroxa-
ban or dabigatran etexilate to edoxaban, as specified in the
study protocol, is based on the totality of data. In total, the
results of this study suggest that switching from dabigatran
etexilate to edoxaban will also maintain patients’ antico-
agulated status. It should be noted that the study has the
limitations of having a small number of subjects, being
open-label and of short duration, and enrolling only heal-
thy, young subjects.
5 Conclusions
Switching from rivaroxaban to edoxaban 24 h after the last
rivaroxaban dose did not affect edoxaban pharmacokinetics
and resulted in similar anticoagulant effects in all phar-
macodynamic assays compared with multiple administra-
tion of edoxaban. Switching from dabigatran etexilate to
edoxaban 12 h after the last dabigatran etexilate dose had
no effect on edoxaban pharmacokinetics. Switching from
dabigatran etexilate to edoxaban resulted in higher anti-
coagulant effects of edoxaban for aPTT and select throm-
bin generation parameters compared with treatment with
edoxaban alone, although previous treatment with dabiga-
tran etexilate did not affect other pharmacodynamic
markers. Overall, the study results suggest that switching to
edoxaban from either rivaroxaban or dabigatran etexilate at
the time of the next dose is well tolerated and maintains
coagulation status in healthy subjects.
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